Video

Dr. Rogers discusses FDA approval of InterStim X system

Author(s):

Urology Times staff

The device is indicated for overactive bladder, chronic fecal incontinence, and non-obstructive urinary retention.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In this video, Alexandra Rogers, MD, comments on the recent FDA approval of the InterStim X system. Rogers is a urologist in Boulder, Colorado.

      Related Videos
      Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
      Study results affirm effectiveness of evolving prostate cancer therapies
      Laura Davis, MD, on link between microplastics and bladder cancer
      Laura Davis, MD, on link between microplastics and bladder cancer
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
      Considerations for patient follow-up after onabotA administration
      Considerations for patient follow-up after onabotA administration
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Mitchell Huang, MD, on the link between obesity and pain on transperineal biopsy
      Administering onabotA: Improving patient comfort and easing anxiety
      Administering onabotA: Improving patient comfort and easing anxiety
      Woman talking with a doctor | Image Credit: © Liudmila Dutko - stock.adobe.com
      Expert discusses genitourinary syndrome of menopause guidelines
      Rebecca A. Campbell, MD, answers a question during a Zoom video interview
      Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
      Joshua Heiman, MD, on phentermine plus topiramate for uric acid stone prevention
      Joshua Heiman, MD, on phentermine plus topiramate for uric acid stone prevention
      Amy Krambeck, MD, on innovation and building strong programs in endourology
      Amy Krambeck, MD, on innovation and building strong programs in endourology
      Related Content
      Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI
      May 16th 2025

      Addressing an unmet need: CELLEBRATE trial explores cell-based therapy for recurrent SUI

      Melissa Kaufman, MD, PhD, FACS Hannah Clarke
      The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.
      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
      March 21st 2022

      Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

      Urology Times staff
      “This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
      Artificial urinary sphincter for SUI shows safety, efficacy in prospective study
      May 9th 2025

      Artificial urinary sphincter for SUI shows safety, efficacy in prospective study

      Melissa Kaufman, MD, PhD, FACS Hannah Clarke
      "This trial will be the benchmark for research reporting in the future," says Melissa R. Kaufman, MD, PhD, FACS.
      Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB
      March 18th 2022

      Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

      Urology Times staff
      “We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.
      First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI
      April 24th 2025

      First patient enrolled in trial of Voro Urologic Scaffold for post-prostatectomy SUI

      Hannah Clarke
      "What is truly exciting is the potential for this device to meaningfully improve early and long-term continence rates, which can profoundly impact a patient's recovery and overall quality of life,” says Patrick Daily, MD.
      Neuromodulation device shows promising efficacy for neurogenic bladder
      April 16th 2025

      Neuromodulation device shows promising efficacy for neurogenic bladder

      Hannah Clarke
      Data from the pivotal CONTINENCE trial showed encouraging efficacy of SCONE neuromodulation therapy.
      © 2025 MJH Life Sciences

      All rights reserved.